KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Accumulated Expenses (2016 - 2025)

Resmed (RMD) has disclosed Accumulated Expenses for 16 consecutive years, with $391.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 11.05% year-over-year to $391.5 million, compared with a TTM value of $391.5 million through Dec 2025, up 11.05%, and an annual FY2025 reading of $402.3 million, up 6.51% over the prior year.
  • Accumulated Expenses was $391.5 million for Q4 2025 at Resmed, down from $395.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $402.3 million in Q2 2025 and bottomed at $274.1 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $345.7 million, with a median of $347.8 million recorded in 2023.
  • Peak annual rise in Accumulated Expenses hit 3756.6% in 2021, while the deepest fall reached 1.57% in 2021.
  • Year by year, Accumulated Expenses stood at $286.8 million in 2021, then increased by 8.84% to $312.2 million in 2022, then increased by 6.4% to $332.1 million in 2023, then increased by 6.14% to $352.5 million in 2024, then increased by 11.05% to $391.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for RMD at $391.5 million in Q4 2025, $395.8 million in Q3 2025, and $402.3 million in Q2 2025.